Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.
Keep your PROTAC projects moving forward with in-solution and mass-independent measurements, data that agree with the latest fit models for three-component systems, and flexibility to succeed in characterizing interactions that include covalent binders.
Have a question about Dianthus?
Contact SpecialistSee more related content
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.

2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...

When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an

Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target

With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat

Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...

There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

Update: See which 2023 conferences you should watch for With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on...

Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...



Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...

Update: See what 2022 conferences you should watch for Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation...

There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t

Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...